Advertisement


Eva M. Ciruelos, MD, PhD, on HER2-Positive and PAM50 Luminal Breast Cancer: Primary Results From the PATRICIA Trial

2024 ASCO Annual Meeting

Advertisement

Eva M. Ciruelos, MD, PhD, of Spain’s Hospital 12 de Octubre and the Instituto de Investigación Sanitaria Hospital 12 de Octubre, discusses phase II data showing that the combination of palbociclib, trastuzumab, and endocrine therapy improved progression-free survival in patients with previously treated PAM50 luminal A or B, HER2-positive advanced breast cancer, as compared with treatment of physicians’ choice (Abstract 1008).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We presented the first primary results of the PATRICIA cohort C trial. This is an open level, phase two randomized trial that recruited HER2-positive advanced breast cancer patients who received an experimental combination consisted on palbociclib, trastuzumab and endocrine therapy versus treatment of physician choice with T-DM1 or the combination of trastuzumab chemotherapy or endocrine treatment. These patients were pre-treated patients, at least two prior lines of treatment, and all of them were selected based on the intrinsic subtyping. Just luminal A and luminal B tumors were included in this trial. Primary result was achieved and progression for survival was significantly improved with combination of palbociclib trastuzumab endocrine treatment over treatment of physician's choice, with a reduction in the risk of progression of about 48%, which is statistically significant. These results are unique as we try to select patients based on a new biomarker, which is intrinsic subtype, and offering this non-chemotherapy combination for these patients that harbored about 50% within the HER-positive HER2-positive disease. Regarding tolerability, no dose reductions were done differently from these two arms and no dose discontinuations were needed in the experimental arm. That is why our conclusions says that this is a new way to classify in patients within the HER2-positive disease. This is a non-chemo alternative for these patients that will translate, for sure, into quality of life. But still we should validate our results as our trial had some limitations due to a small sample size, so maybe new prospective randomized designs will be needed to confirm our [inaudible 00:02:21] results.

Related Videos

Lung Cancer

Narjust Florez, MD, and David R. Spigel, MD, on Limited-Stage Small Cell Lung Cancer: Results From the ADRIATIC Study

Narjust Florez, MD, of Dana-Farber Cancer Institute, and David R. Spigel, MD, of Sarah Cannon Research Institute, discuss phase III findings showing that durvalumab as consolidation treatment after concurrent platinum-based chemoradiotherapy improved survival outcomes compared with placebo in patients with limited-stage small cell lung cancer. According to Dr. Spigel, these data support durvalumab as a new standard of care in this population (Abstract LBA5).

Skin Cancer

Pauline Funchain, MD, and Caroline Robert, MD, PhD, on Melanoma: New Data on Encorafenib, Binimetinib, Ipilimumab, and Nivolumab

Pauline Funchain, MD, of Stanford University, and Caroline Robert, MD, PhD, of Gustave Roussy, discuss phase II findings showing that combining encorafenib and binimetinib followed by ipilimumab and nivolumab vs ipilimumab and nivolumab can improve progression-free survival in patients with BRAF-V600E/K-mutated melanoma characterized by high lactate dehydrogenase and liver metastases (Abstract LBA9503).

Kidney Cancer

Laurence Albiges, MD, PhD, on Renal Cell Carcinoma: Biomarker Analysis of the IMmotion010 Study

Laurence Albiges, MD, PhD, of Gustave Roussy, Université Paris-Saclay, discusses phase III findings showing that high baseline serum KIM-1 levels were associated with poorer prognosis but improved clinical outcomes with atezolizumab vs placebo in patients with renal cell carcinoma at increased risk of recurrence after resection. Increased post-treatment KIM-1 levels were found to be associated with worse disease-free survival (Abstract 4506).

Lymphoma

Yasmin H. Karimi, MD, on Diffuse Large B-Cell Lymphoma: Update on Use of Epcoritamab Plus Chemotherapy

Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses data reaffirming the efficacy and feasibility of using epcoritamab plus R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin) in autologous stem cell transplant–eligible patients with diffuse large B-cell lymphoma. Response rates were reported to be high, and most patients proceeded to transplant (Abstract 7032).

Lung Cancer

Tony S.K. Mok, MD, on NSCLC: Adagrasib vs Docetaxel in KRAS G12C–Mutated Disease

Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses phase III findings from the KRYSTAL-12 study, which showed that adagrasib improved progression-free survival and overall response rate over docetaxel in patients with locally advanced or metastatic non–small cell lung cancer harboring a KRAS G12C mutation who had previously received a platinum-based chemotherapy with anti–PD-(L)1 treatment.

Advertisement

Advertisement




Advertisement